The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Is Artificial Intelligence Echoing Human Bias in Cancer Care?
By The Cancer News Team
Exploring AI’s role in cancer care, from early diagnosis to drug discovery, while addressing bias and health disparities.
Is Artificial Intelligence Echoing Human Bias in Cancer Care?
By The Cancer News Team
Exploring AI’s role in cancer care, from early diagnosis to drug discovery, while addressing bias and health disparities.
Is Artificial Intelligence Echoing Human Bias in Cancer Care?
By The Cancer News Team
Exploring AI’s role in cancer care, from early diagnosis to drug discovery, while addressing bias and health disparities.
Kidney Cancer Awareness Month
By The Cancer News Team
March is Kidney Cancer Awareness Month, highlighting genitourinary cancers, immunotherapy, and global efforts by Binaytara to improve cancer care equity.
Kidney Cancer Awareness Month
By The Cancer News Team
March is Kidney Cancer Awareness Month, highlighting genitourinary cancers, immunotherapy, and global efforts by Binaytara to improve cancer care equity.
Kidney Cancer Awareness Month
By The Cancer News Team
March is Kidney Cancer Awareness Month, highlighting genitourinary cancers, immunotherapy, and global efforts by Binaytara to improve cancer care equity.
National Colorectal Cancer Awareness Month
By Binaytara Team
Colorectal cancer is preventable with early screening. Learn about risk factors, symptoms, and prevention strategies this National Colorectal Cancer Awareness Month
National Colorectal Cancer Awareness Month
By Binaytara Team
Colorectal cancer is preventable with early screening. Learn about risk factors, symptoms, and prevention strategies this National Colorectal Cancer Awareness Month
National Colorectal Cancer Awareness Month
By Binaytara Team
Colorectal cancer is preventable with early screening. Learn about risk factors, symptoms, and prevention strategies this National Colorectal Cancer Awareness Month
ASCO24 LAURA Trial Summary
By Editorial Team
By: Zhiting Tang1, Lei Deng2 1\. [Unity Hospital](https://www.rochesterregional.org/locations/unity-hospital), Rochester Regional Health, Rochester, NY 2\. [University of Washington](https://www.uw...
ASCO24 LAURA Trial Summary
By Editorial Team
By: Zhiting Tang1, Lei Deng2 1\. [Unity Hospital](https://www.rochesterregional.org/locations/unity-hospital), Rochester Regional Health, Rochester, NY 2\. [University of Washington](https://www.uw...
ASCO24 LAURA Trial Summary
By Editorial Team
By: Zhiting Tang1, Lei Deng2 1\. [Unity Hospital](https://www.rochesterregional.org/locations/unity-hospital), Rochester Regional Health, Rochester, NY 2\. [University of Washington](https://www.uw...
ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)
By Editorial Team
By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. [Department of Internal Medicine, University of Central Florida](https://med.ucf.edu/), Pensacola, FL 2. [Mayo Clinic](https://www.mayoclinic.org/patien...
ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)
By Editorial Team
By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. [Department of Internal Medicine, University of Central Florida](https://med.ucf.edu/), Pensacola, FL 2. [Mayo Clinic](https://www.mayoclinic.org/patien...
ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)
By Editorial Team
By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. [Department of Internal Medicine, University of Central Florida](https://med.ucf.edu/), Pensacola, FL 2. [Mayo Clinic](https://www.mayoclinic.org/patien...
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
A Latino Lens
By Editorial Team
### **Listening to the Community to Fuel Outreach and Engagement** **By Dr. Kelly Meza** Dr. Ramirez and her team at Mays Cancer Center are dedicated to tackling the unequal impact of cancer an...
A Latino Lens
By Editorial Team
### **Listening to the Community to Fuel Outreach and Engagement** **By Dr. Kelly Meza** Dr. Ramirez and her team at Mays Cancer Center are dedicated to tackling the unequal impact of cancer an...
A Latino Lens
By Editorial Team
### **Listening to the Community to Fuel Outreach and Engagement** **By Dr. Kelly Meza** Dr. Ramirez and her team at Mays Cancer Center are dedicated to tackling the unequal impact of cancer an...
A Digital Solution: Clinical Trials Without Adverse Events
By The Cancer News Team
Clinical trials are the process by which progress is made in clinical care. It is accepted and understood that participants in clinical trials must be assessed for both toxicity and efficacy, but what...
A Digital Solution: Clinical Trials Without Adverse Events
By The Cancer News Team
Clinical trials are the process by which progress is made in clinical care. It is accepted and understood that participants in clinical trials must be assessed for both toxicity and efficacy, but what...
A Digital Solution: Clinical Trials Without Adverse Events
By The Cancer News Team
Clinical trials are the process by which progress is made in clinical care. It is accepted and understood that participants in clinical trials must be assessed for both toxicity and efficacy, but what...
A 12 Year Journey to Enhance Minority Enrollment in Clinical Trials
By Binaytara Team
Dr. Sharad Ghamande, MD, FACOG delivered an insightful presentation titled "Can We Increase Accrual of Minorities in Rural Areas of the Country? A 12-Year Journey," shedding light on the imperative ne...
A 12 Year Journey to Enhance Minority Enrollment in Clinical Trials
By Binaytara Team
Dr. Sharad Ghamande, MD, FACOG delivered an insightful presentation titled "Can We Increase Accrual of Minorities in Rural Areas of the Country? A 12-Year Journey," shedding light on the imperative ne...
A 12 Year Journey to Enhance Minority Enrollment in Clinical Trials
By Binaytara Team
Dr. Sharad Ghamande, MD, FACOG delivered an insightful presentation titled "Can We Increase Accrual of Minorities in Rural Areas of the Country? A 12-Year Journey," shedding light on the imperative ne...
Access to Medications: Cases Studies in Solutions
By Editorial Team
**By Dr. Richa Parikh** In this talk, Dr. Dan Milner discusses various strategies to improve access to oncology drugs to patients both in the US and globally, in an equitable manner to mitigate disp...
Access to Medications: Cases Studies in Solutions
By Editorial Team
**By Dr. Richa Parikh** In this talk, Dr. Dan Milner discusses various strategies to improve access to oncology drugs to patients both in the US and globally, in an equitable manner to mitigate disp...
Access to Medications: Cases Studies in Solutions
By Editorial Team
**By Dr. Richa Parikh** In this talk, Dr. Dan Milner discusses various strategies to improve access to oncology drugs to patients both in the US and globally, in an equitable manner to mitigate disp...